Broadly neutralizing antibodies (bNAbs) offer promising opportunities for preventing HIV-1 infection. The protection mechanisms of bNAbs involve the Fc domain, as well as their Fab counterpart. Here, different bNAb isotypes including IgG1, IgA1, IgA2, and IgA122 (IgA2 with the hinge of IgA1) were generated and then produced in CHO cells. Their ability to neutralize pseudovirus and primary HIV-1 isolates were measured, as well as their potential ADCC-like activity using a newly developed assay. In our work, gp41-specific IgA seems to be more efficient than IgG1 in inducing ADCC-like activity, but not in its virus neutralization effect. We show that either gp120-specific IgA or IgG1 isotypes are both efficient in neutralizing different viral strains. In contrast, gp120-specific IgG1 was a better ADCC-like inducer than IgA isotypes. These results provide new insights into the neutralization and ADCC-like activity of different bNAbs that might be taken into consideration when searching for new treatments or antibody-based vaccines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227833 | PMC |
| http://dx.doi.org/10.3390/vaccines10060903 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antiviral Activities of HIV-1-Specific Human Broadly Neutralizing Antibodies Are Isotype-Dependent.
Vaccines (Basel)
June 2022
CIRI-Centre International de Recherche en Infectiologie, Team GIMAP, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, CIC 1408 Vaccinology, 42023 Saint-Etienne, France.
Broadly neutralizing antibodies (bNAbs) offer promising opportunities for preventing HIV-1 infection. The protection mechanisms of bNAbs involve the Fc domain, as well as their Fab counterpart. Here, different bNAb isotypes including IgG1, IgA1, IgA2, and IgA122 (IgA2 with the hinge of IgA1) were generated and then produced in CHO cells.
View Article and Find Full Text PDFRegulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents.
Transplantation
February 2014
1 Transplant Immunology Laboratory, Comprehensive Transplant Center, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA. 2 Comprehensive Transplant Center, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA. 3 Biostatistics Core, Research Institute, General Clinical Research Center, Cardiothoracic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA. 4 Address correspondence to: Bong-Ha Shin, Ph.D., Transplant Immunology Laboratory, SSB111, Comprehensive Transplant Center, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048.
Background: It was demonstrated that human natural killer (NK) cells, via antibody-dependent cellular cytotoxicity (ADCC)-like mechanism, increase IFNγ production after exposure to alloantigens. This finding was associated with an increased risk for antibody-mediated rejection (ABMR). Although the effects of various immunosuppressive drugs on T cells and B cells have been extensively studied, their effects on NK cells are less clear.
View Article and Find Full Text PDFNK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.
J Cell Mol Med
March 2012
Pediatric Hematology and Oncology, University Hospital, Frankfurt am Main, Germany.
Treatment of high-risk neuroblastoma (NB) represents a major challenge in paediatric oncology. Alternative therapeutic strategies include antibodies targeting the disialoganglioside GD(2) , which is expressed at high levels on NB cells, and infusion of donor-derived natural killer (NK) cells. To combine specific antibody-mediated recognition of NB cells with the potent cytotoxic activity of NK cells, here we generated clonal derivatives of the clinically applicable human NK cell line NK-92 that stably express a GD(2) -specific chimeric antigen receptor (CAR) comprising an anti-GD(2) ch14.
View Article and Find Full Text PDFEffect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
Cancer Res
December 1988
Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892.
We have previously shown that treatment of C57BL/6 mice with specific anti-B16 melanoma monoclonal antibody (Mab) significantly reduced the number of established liver metastases. In this paper we show that when treatment with Mab was applied to mice bearing both liver and lung micrometastases, the number of liver metastases was reduced by 72-98%, whereas no effect was seen on the number of lung metastases. In contrast to results obtained when treating liver metastases, treatment of B16 melanoma lung metastases with Mab and recombinant interleukin 2 was unsuccessful when recombinant interleukin 2 was given concomitantly or after priming with high doses of recombinant interleukin 2.
View Article and Find Full Text PDFInduction of cell-mediated cytotoxicity by shark 19S IgM.
Cell Immunol
January 1988
Department of Microbiology & Immunology, University of Miami School of Medicine, Florida 33101.
Plasma from unimmunized nurse sharks can mediate a reaction similar to antibody-dependent cell-mediated cytotoxicity (ADCC). Normal shark plasma contains numerous natural antibodies reactive with a variety of antigens, including the target employed. Adsorption of plasma with target cells removed a significant amount of activity, suggesting involvement of antibody.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!